Negative functional effects of natriuretic peptides are attenuated in hypertrophic cardiac myocytes by reduced particulate guanylyl cyclase activity

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 2, 2007, Pages 100-105

  Meyer, Mark ^a   Zhang, Qihang ^a   Khurana, Kiranpreet ^a   Scholz, Peter M ^a   Weiss, Harvey R ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cardiac myocyte function; Cyclic GMP; Guanylyl cyclase; Natriuretic peptides; Rabbit; Thyroxine

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; GUANYLATE CYCLASE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; THYROXINE; ZAPRINAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HEART CONTRACTION; HEART MUSCLE CELL; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; NONHUMAN; PRIORITY JOURNAL; RABBIT; VIDEORECORDING;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; CELL SIZE; CYCLIC GMP; GUANYLATE CYCLASE; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NATRIURETIC PEPTIDES; PHOSPHODIESTERASE INHIBITORS; PURINONES; RABBITS; THYROXINE;

EID: 33847239584     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802e84db     Document Type: Article

References (30)

1. Kuhn M. Molecular physiology of natriuretic peptide signaling. Basic Res Cardiol. 2004;99:76-82.
2. Tremblay J, Desjardins R, Hum D, et al. Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases. Mol Cell Biochem. 2002;230:31-47.
3. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors and cGMP-dependent signaling function. Endocrine Rev. 2006;27:47-72.
4. Lohmann SM, Fischmeister R, Walter U. Signal transduction by cGMP in heart. Bas Res Cardiol. 1991;86:503-514.
5. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther. 2000;86:49-86.
6. Zhang Q, Moalem J, Tse J, et al. Effects of natriuretic peptides on ventricular myocyte contraction and role of cyclic GMP signaling. Eur J Pharmacol. 2005;510:209-215.
7. Engel S, Yan L, Weiss HR, et al. Negative functional effects of cGMP mediated by cGMP protein kinase are reduced in T4 cardiac myocytes. Eur J Pharmacol. 2001;421:23-30.
8. Sperelakis N, Tohse N, Ohya Y, et al. Cyclic GMP regulation of calcium slow channels in cardiac muscle and vascular smooth muscle cells. Adv Pharmacol. 1994;26:217-252.
9. Francis CS. Pathophysiology of chronic heart failure. Am J Med. 2001;110(Suppl 7A):37S-46S.
10. Sadoff JD, Scholz PM, Tse J, et al. Increased guanylate cyclase activity is associated with an increase in cyclic guanosine 3′, 5′-monophosphate in left ventricular hypertrophy. J Clin Invest. 1996;98:838-845.
11. 4-induced cardiac hypertrophy. Am J Physiol. 1995;268:H686-H691.
12. Chilian WM, Wangler RD, Peters KG, et al. Thyroxine-induced left ventricular hypertrophy in the rat. Circ Res. 1985;57:591-598.
13. Eliades D, Weiss HR. Role of beta-adrenoceptors in the hypertrophic response to thyroxine. J Cardiovasc Pharmacol. 1989;14:58-65.
14. Anjos-Ramos L, Carneiro-Ramos MS, Diniz GP, et al. Early cardiac hypertrophy induced by thyroxine is accompanied by an increase in VEGF-A expression but not by an increase in capillary density. Virchows Arch. 2006;448:472-479.
15. Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid hormone receptor specific nuclear and extra nuclear actions. Mol Cell Endocrinol. 2003;31:1-11.
16. Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. Thyroid 2002;12:459-466.
17. Yan L, Zhang Q, Scholz PM, et al. Cyclic GMP protein kinase activity is reduced in thyroxine-induced hypertrophic cardiac myocytes. Clin Exper Pharmacol Physiol. 2003;30:943-950.
18. Su J, Zhang Q, Moalem J, et al. Functional effects of C-type natriuretic peptide and nitric oxide are attenuated in hypertrophic myocytes from pressure-overloaded mouse hearts. Am J Physiol. 2005;288:H1367-H1373.
19. Tajima M, Bartunek J, Weinberg EO, et al. Atrial natriuretic peptide has different effects on contractility and intracellular pH in normal and hypertrophied myocytes from pressure-overloaded hearts. Circulation. 1998;98:2760-2764.
20. Gong GX, Weiss HR, Tse J, et al. Cyclic GMP decreases cardiac myocyte oxygen consumption to a greater extent under conditions of increased metabolism. J Cardiovasc Pharmacol. 1997;30:537-543.
21. Agullo L, Garcia-Dorado N, Escalona M, et al. Effect of ischemia on soluble and particulate guanylyl cyclase-mediated cGMP synthesis in cardiomyocytes. Am J Physiol. 2003;284:H2170-H2176.
22. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther. 2004;101:113-129.
23. Matsukawa N, Grzesik WJ, Takahashi N, et al. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA. 1999;96:7403-7408.
24. Potthast R, Potter LR. Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptors. Peptides 2005;26:1001-1008.
25. +2ATPase. Pharmacol. 2002;64:106-112.
26. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann Rev Biochem. 1994;63:451-486.
27. Wolska BM, Averyhart-Fullard V, Omachi A, et al. Changes in thyroid state affect pHi and Nai+ homeostasis in rat ventricular myocytes. J Molec Cell Cardiol. 1997;29:2653-2663.
28. Smolenski A, Burkhardt AM, Eigenthaler M, et al. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn Schmiedebergs Arch Pharmacol. 1998;358:134-139.
29. Abbey SE, Potter LR. Vasopressin-dependent inhibition of the C-type natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular calcium concentrations. J Biol Chem. 2002;277:42423-42430.
30. Walther T, Siems W-E, Hauke D, et al. AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. FASEB J. 2002;16:1237-1241.